https://www.aktx.com/en/news/veloxis-pharmaceuticals-receives-approval-from-usan-for-pegrizeprument-as-nonproprietary-name-for-vel-101/2026-02-13T11:17:35-05:00https://www.aktx.com/en/news/calliditas-therapeutics-to-present-four-abstracts-at-american-society-of-nephrology-asn-kidney-week-2024/2026-01-20T16:31:15-05:00https://www.aktx.com/en/news/veloxis-pharmaceuticals-announces-dosing-of-the-first-participant-in-a-phase-i-study-of-vel-101/2026-01-21T14:20:27-05:00https://www.aktx.com/en/news/veloxis-pharmaceuticals-vel-101-granted-fda-fast-track-designation/2026-01-21T14:34:00-05:00https://www.aktx.com/en/news/ose-immunotherapeutics-and-veloxis-pharmaceuticals-enter-into-global-license-agreement/2026-09-13T14:58:35-04:00https://www.aktx.com/en/news/fda-approves-new-indication-for-envarsus-xr-tacrolimus-extended-release-tablets/2026-01-23T11:14:06-05:00https://www.aktx.com/en/news/veloxis-launches-envarsusxr-for-treatment-of-kidney-transplant-patients-in-us/2026-02-13T11:40:24-05:00https://www.aktx.com/en/news/calliditas-partner-stada-receives-positive-chmp-opinion-recommending-full-approval-for-kinpeygo/2026-09-13T15:18:33-04:00https://www.aktx.com/en/news/calliditas-partner-stada-receives-european-commission-decision-for-full-approval-of-kinpeygosupreg-for-the-treatment-of-iga-nephropathy/2026-09-13T15:18:08-04:00https://www.aktx.com/en/news/us-fda-accepts-veloxis-new-drug-application-for-envarsus-for-the-prevention-of-organ-rejection-in-kidney-transplant-patients/2026-09-13T14:35:24-04:00https://www.aktx.com/en/news/aicuris-receives-fda-priority-review-for-pritelivir-nda-and-presents-new-phase-3-data-at-escmid-2026/2026-09-13T15:38:22-04:00https://www.aktx.com/en/news/asahi-kasei-to-acquire-aicuris-to-accelerate-growth-in-severe-infectious-diseases/2026-09-13T15:40:19-04:00https://www.aktx.com/en/news/pritelivir-demonstrates-superior-efficacy-in-people-living-with-hiv-with-refractory-hsv-in-phase-3-prioh-1/2026-09-13T15:42:48-04:00https://www.aktx.com/en/news/aicuris-presents-positive-phase-3-data-for-pritelivir-in-immunocompromised-patients-with-refractory-herpes-simplex-virus-at-tandem/2026-09-13T15:44:04-04:00https://www.aktx.com/en/news/aicuris-announces-pritelivir-phase-3-hsv-data-to-be-presented-as-late-breaking-oral-presentation-at-tandem/2026-09-13T15:45:04-04:00https://www.aktx.com/en/news/aicuris-presents-positive-phase-2-results-for-pritelivir-and-favorable-phase-1-safety-data-for-aic468-at-id-week-2025/2026-09-09T11:28:46-04:00https://www.aktx.com/en/news/aicuris-announces-pritelivir-met-primary-endpoint-in-immunocompromised-herpes-simplex-virus-infected-patients-in-phase-3-pivotal-trial/2026-09-13T15:28:41-04:00https://www.aktx.com/en/news/aicuris-announces-upcoming-oral-and-poster-presentations-at-id-week-2025/2026-09-13T15:30:40-04:00https://www.aktx.com/en/news/aicuris-presents-pharmacokinetic-data-from-the-first-in-human-clinical-trial-of-aic468-a-novel-antisense-oligonucleotide-targeting-bk-virus-at-world-transplant-congress/2026-09-13T15:31:10-04:00https://www.aktx.com/en/news/aicuris-enrolled-last-participant-in-pivotal-trial-with-pritelivir-to-treat-refractory-herpes-simplex-infection-in-immunocompromised-patients/2026-09-13T15:32:04-04:00https://www.aktx.com/en/news/aicuris-initiates-first-in-human-phase-1-trial-with-antiviral-agent-aic468-to-address-bk-virus-infections-in-kidney-transplant-recipients/2026-09-13T15:16:38-04:00https://www.aktx.com/en/news/veloxis-pharmaceuticals-showcases-research-at-the-2026-american-transplant/2026-09-13T15:36:25-04:00https://www.aktx.com/en/news/pegrizeprument-granted-orphan-drug-designation-for-prevention-of-organ-749183/2026-09-13T15:37:00-04:00https://www.aktx.com/en/news/pegrizeprument-granted-orphan-drug-designation-for-prevention-of-organ-666801/2026-09-13T15:45:45-04:00https://www.aktx.com/en/news/veloxis-pharmaceuticals-selected-to-present-at-the-2024-american-transplant/2026-09-13T15:20:32-04:00https://www.aktx.com/en/news/c-paths-transplant-therapeutics-consortium-receives-ema-draft-qualification/2026-09-13T15:04:26-04:00https://www.aktx.com/en/news/transplant-therapeutics-consortium-receives-acceptance-of-letter-of-intent-for/2026-09-13T14:57:11-04:00https://www.aktx.com/en/news/calliditas-therapeutics-ab-to-present-exploratory-biomarker-and-post-hoc/2026-09-13T15:39:29-04:00https://www.aktx.com/en/news/calliditas-partner-everest-medicines-starts-commercial-launch-of-nefecon-in/2026-09-13T15:20:55-04:00https://www.aktx.com/en/news/calliditas-announces-an-additional-seven-year-orphan-drug-exclusivity-period/2026-09-13T15:21:17-04:00https://www.aktx.com/en/news/calliditas-therapeutics-announces-full-fda-approval-of-tarpeyo-the-only-fda/2026-09-13T15:12:09-04:00https://www.aktx.com/en/news/calliditas-partner-everest-medicines-announces-china-nmpas-approval-of-nefecon/2026-09-13T15:12:36-04:00https://www.aktx.com/en/news/new-drug-application-approval-by-the-pharmaceutical-administration-bureau-of/2026-09-13T15:12:59-04:00https://www.aktx.com/en/news/calliditas-announces-filing-with-uk-mhra-for-kinpeygo-in-iga-nephropathy/2026-09-13T15:13:19-04:00https://www.aktx.com/en/news/stada-and-calliditas-announce-the-filing-for-full-marketing-authorization-of/2026-09-13T15:13:58-04:00https://www.aktx.com/en/news/fda-grants-priority-review-for-full-approval-of-tarpeyo-for-the-treatment-of/2026-09-13T15:14:36-04:00https://www.aktx.com/en/news/calliditas-therapeutics-submits-supplemental-new-drug-application-to-us-food/2026-09-13T15:15:17-04:00https://www.aktx.com/en/news/calliditas-receives-conditional-marketing-authorization-from-uk-mhra-for/2026-09-13T15:15:41-04:00https://www.aktx.com/en/news/calliditas-therapeutics-announces-license-agreement-with-viatris-to-register/2026-09-13T15:00:38-04:00https://www.aktx.com/en/news/calliditas-partner-everest-medicines-new-drug-application-for-nefecon-is/2026-09-13T15:01:07-04:00https://www.aktx.com/en/news/calliditas-partner-stada-launches-the-first-medicine-authorized-in-the-eu-for/2026-09-13T15:05:12-04:00https://www.aktx.com/en/news/european-commission-approves-kinpeygo-for-adults-with-primary-iga-nephropathy/2026-09-13T15:05:42-04:00https://www.aktx.com/en/news/calliditas-receives-positive-chmp-opinion-in-iga-nephropathy/2026-09-13T15:06:12-04:00https://www.aktx.com/en/news/expansion-of-everest-medicines-licence-agreement-to-include-south-korea/2026-09-13T15:07:06-04:00https://www.aktx.com/en/news/calliditas-therapeutics-announces-commercial-availability-and-initial-sales-of/2026-09-13T15:11:09-04:00https://www.aktx.com/en/news/fda-grants-calliditas-therapeutics-accelerated-approval-of-tarpeyo-budesonide/2026-09-13T14:57:53-04:00https://www.aktx.com/en/news/calliditas-therapeutics-and-stada-partner-to-register-and-commercialize/2026-09-13T14:58:06-04:00https://www.aktx.com/en/news/fda-grants-priority-review-for-nefecon-for-patients-with-iga-nephropathy/2026-09-13T14:58:21-04:00https://www.aktx.com/en/news/ema-grants-accelerated-assessment-procedure-for-nefecon-for-the-treatment-of/2026-09-13T14:58:50-04:00https://www.aktx.com/en/news/calliditas-announces-submission-of-new-drug-application-to-us-fda-for-nefecon/2026-09-13T14:59:03-04:00https://www.aktx.com/en/news/calliditas-therapeutics-and-everest-medicines-enter-into-an-agreement-to/2026-09-13T14:56:31-04:00https://www.aktx.com/en/news/veloxis-pharmaceuticals-doses-first-patient-in-rengevity-201-phase-2-trial-of-pegrizeprument-for-the-prevention-of-organ-rejection-in-kidney-transplant-recipients/2026-09-25T15:16:36-04:00